Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00351546
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00351585
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2007-05-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 236
- Registration Number
- NCT00351832
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 79
- Registration Number
- NCT00351130
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 184
- Registration Number
- NCT00351052
Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel
Phase 4
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00350155
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 647
- Registration Number
- NCT00350168
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corp, E. Hanover, New Jersey, United States
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
Phase 4
Terminated
- Conditions
- Chronic Constipation
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00348634
- Locations
- 🇺🇸
Arkansas Gastroenterology, PA, North Little Rock, Arizona, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 768
- Registration Number
- NCT00344110
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Japan, Japan
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
Phase 3
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 654
- Registration Number
- NCT00343551
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
© Copyright 2025. All Rights Reserved by MedPath